Acetate → Octreotide

HRID 2424242

反応式

HRID 2424242 の反応式
[CH3:1][C@@H:2]([OH:71])[C@@H:3]1[NH:27][C:25](=[O:26])[C@H:24]([CH2:28][CH2:29][CH2:30][CH2:31][NH2:32])[NH:23][C:21](=[O:22])[C@@H:20]([CH2:33][C:34]2[C:38]3[CH:39]=[CH:40][CH:41]=[CH:42][C:37]=3[NH:36][CH:35]=2)[NH:19][C:17](=[O:18])[C@H:16]([CH2:43][C:44]2[CH:45]=[CH:46][CH:47]=[CH:48][CH:49]=2)[NH:15][C:13](=[O:14])[C@@H:12]([NH:50][C:51]([C@H:53]([NH2:61])[CH2:54][C:55]2[CH:56]=[CH:57][CH:58]=[CH:59][CH:60]=2)=[O:52])[CH2:11][S:10][S:9][CH2:8][C@@H:7]([C:62]([NH:64][C@@H:65]([C@H:68]([OH:70])[CH3:69])[CH2:66][OH:67])=[O:63])[NH:6][C:4]1=[O:5].C1(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O.C([O-])(=O)C.C([O-])(=O)CC(CC([O-])=O)(C([O-])=O)O>>[CH3:1][C@@H:2]([OH:71])[C@@H:3]1[NH:27][C:25](=[O:26])[C@H:24]([CH2:28][CH2:29][CH2:30][CH2:31][NH2:32])[NH:23][C:21](=[O:22])[C@@H:20]([CH2:33][C:34]2[C:38]3[CH:39]=[CH:40][CH:41]=[CH:42][C:37]=3[NH:36][CH:35]=2)[NH:19][C:17](=[O:18])[C@H:16]([CH2:43][C:44]2[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=2)[NH:15][C:13](=[O:14])[C@@H:12]([NH:50][C:51]([C@H:53]([NH2:61])[CH2:54][C:55]2[CH:60]=[CH:59][CH:58]=[CH:57][CH:56]=2)=[O:52])[CH2:11][S:10][S:9][CH2:8][C@@H:7]([C:62]([NH:64][C@@H:65]([C@H:68]([OH:70])[CH3:69])[CH2:66][OH:67])=[O:63])[NH:6][C:4]1=[O:5]

参加物

4

反応物 3

HCID 175AcetateHCID 31348CitrateHCID 86603142HCID 86603142、化合物

生成物 1

HCID 448601Octreotide

実験手順

Poly(DL-lactide-co-glycolide) (PLGA) having a 50/50 ratio of lactide to glycolide (DL2.5A from Alkermes) was dissolved in N-methyl-2-pyrrolidone (NMP), or methoxypolyethylene glycohol (mPEG) to give a 40% solution by weight. The injectable polymer solutions were prepared by dispersing octreotide phytate or acetate or citrate. The mixture was thoroughly mixed until a uniform suspension or solution was obtained. Injectable formulations were prepared as shown below.

後処理

  1. customThe injectable polymer solutions were prepared
  2. additionThe mixture was thoroughly mixed until a uniform suspension
  3. customsolution was obtained
  4. customInjectable formulations were prepared

出典と根拠

ORDレコード
ord-79a3749a68ec4e15bafae9d5be21d4d9
出典データセット
uspto-grants-2011_06
特許番号
US07964219B2

関連ノート

読み込み中…